NAMPT inhibitor-linker 1 is primarily utilized in the field of targeted cancer therapy. It functions as a key component in antibody-drug conjugates (ADCs), where it links a potent NAMPT inhibitor to a monoclonal antibody. This design allows for the precise delivery of the inhibitor to cancer cells, minimizing damage to healthy tissues. The NAMPT inhibitor disrupts the NAD+ biosynthesis pathway, which is crucial for cancer cell survival and proliferation, leading to targeted cell death. This approach enhances the efficacy of cancer treatments while reducing systemic toxicity, making it a promising strategy in oncology research and therapy development.